Previously we showed that none of G2 checkpoint inhibitors resensitized glioma cells with MMR deficiency, suggesting that it was hard to enhance TMZ-induced cytotoxicity in MMR-deficient cells by modifying O6-methylguanine-related pathway [23]. This evidence concerns the gene MRC1 and mismatch repair cancer syndrome 1.